Haemostasis March 2025 Journal Club

Keep informed about evolving science and clinical practice with our March 2025 compilation of the latest studies, guidelines, and perspectives in haemostasis.

GUIDELINES

• Devreese KMJ, Bertolaccini ML, Branch DW, et al. An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. J Thromb Haemost. 2025;23(2):731-744. doi:10.1016/j.jtha.2024.10.022
• Escobar M, Lassila R, Bekdache C, et al. Use of antithrombotic therapy in patients with hemophilia: a selected synopsis of the European Hematology Association – International Society on Thrombosis and Haemostasis – European Association for Hemophilia and Allied Disorders – European Stroke Organization Clinical Practice Guidance document. J Thromb Haemost. 2025;23(2):745-749. doi:10.1016/j.jtha.2024.10.033

PERSPECTIVES & REVIEWS

• Albert CM. Oral anticoagulation in device patients with atrial high-rate episodes: Shared decision-making after ARTESIA and NOAH-AFNET-6. Circulation. 2024;150(18):1398-1400. doi:10.1161/CIRCULATIONAHA.124.068018
• Angiolillo DJ, Capodanno D. Uncoupling Thrombosis and Hemostasis by Inhibiting Factor XI. N Engl J Med. 2025;392(4):400-403. doi:10.1056/NEJMe2414209
• Liu C, Guo C, Li F, et al. Intra-Arterial Urokinase After Endovascular Reperfusion for Acute Ischemic Stroke: The POST-UK Randomized Clinical Trial. JAMA. 2025;333(7):589-598. doi:10.1001/jama.2024.23480
• Mishra DK, Rath A, Parihar M, et al. Current Diagnosis of Bleeding Disorders in Lower Income Countries. Int J Lab Hematol. 2025;47(1):36-40. doi:10.1111/ijlh.14377
• Risman RA, Sen M, Tutwiler V, et al. Deconstructing fibrin(ogen) structure. J Thromb Haemost. 2025;23(2):368-380. doi:10.1016/j.jtha.2024.10.024

CLINICAL TRIALS

• Barakzie A, Jansen AJG, Cavalcante F, et al. Association of primary and secondary hemostasis biomarkers with acute ischemic stroke outcome in patients undergoing thrombectomy, with or without thrombolytics: post hoc analysis of the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands-NO IV. J Thromb Haemost. 2025;23(1):235-247. doi:10.1016/j.jtha.2024.10.008
• Chapin J, Álvarez Román MT, Ayash-Rashkovsky M, et al. A phase 1/2 safety and efficacy study of TAK-754 gene therapy: The challenge of achieving durable factor VIII expression in haemophilia A clinical trials. Haemophilia. 2025;31(1):108-117. doi:10.1111/hae.15121
• Dunn A, Dargaud Y, Abajas Y, et al. Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors. Haemophilia. 2025;31(1):78-86. doi:10.1111/hae.15109
• Huang J, Yang J, Liu C, et al. Intra-Arterial Tenecteplase Following Endovascular Reperfusion for Large Vessel Occlusion Acute Ischemic Stroke: The POST-TNK Randomized Clinical Trial. JAMA. 2025;333(7):579-588. doi:10.1001/jama.2024.23466
• van Ginkel DJ, Bor WL, Aarts HM, et al. Continuation versus Interruption of Oral Anticoagulation during TAVI. N Engl J Med. 2025;392(5):438-449. doi:10.1056/NEJMoa2407794
• Goldenberg NA, Schulman S, Kittelson JM, et al. Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 years. J Thromb Haemost. 2025;23(2):651-656. doi:10.1016/j.jtha.2024.09.038
• Kessakorn N, Gosriwatana I, Sasipong N, et al. Low-Dose Emicizumab Versus Low-/Intermediate-Dose Factor VIII Secondary Prophylaxis for Noninhibitor Haemophilia A Patients With Severe Bleeding Phenotype. Haemophilia. 2025;31(1):122-131. doi:10.1111/hae.15146
• Kirienko AI, Leontyev SG, Tereschenko SN, et al. Non-immunogenic recombinant staphylokinase versus alteplase for patients with massive pulmonary embolism: a randomized open-label, multicenter, parallel-group, non-inferiority trial, FORPE. J Thromb Haemost. 2025;23(2):657-667. doi:10.1016/j.jtha.2024.09.035
• Ling L, Liu C, Huang X, et al. Anti-Xa Activity Test Is Needed but Is Not Enough for Monitoring Fondaparinux Therapy Among Critically Ill Patients. Arch Pathol Lab Med. 2025;149(1):e11-e18. doi:10.5858/arpa.2023-0496-OA
• Liu C, Guo C, Li F, et al. Intra-Arterial Urokinase After Endovascular Reperfusion for Acute Ischemic Stroke: The POST-UK Randomized Clinical Trial. JAMA. 2025;333(7):589-598. doi:10.1001/jama.2024.23480
• Piccini JP, Patel MR, Steffel J, et al. Asundexian versus Apixaban in Patients with Atrial Fibrillation. N Engl J Med. 2025;392(1):23-32. doi:10.1056/NEJMoa2407105
• Ruff CT, Patel SM, Giugliano RP, et al. Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation. N Engl J Med. 2025;392(4):361-371. doi:10.1056/NEJMoa2406674
• Wahid L, Froess JD, Ortel TL, et al. On-Treatment Change in d-Dimer Is Associated With Differential Outcomes Among Therapeutic Dose Heparin-Treated Noncritically Ill Patients Hospitalized for COVID-19. Arterioscler Thromb Vasc Biol. 2025;45(1):162-164. doi:10.1161/ATVBAHA.124.321108
• Zheng Y, Li S, Liu X, et al. Effect of Oral Anticoagulants in Atrial Fibrillation Patients with Polypharmacy: A Meta-analysis. Thromb Haemost. 2025;125(2):166-177. doi:10.1055/s-0043-1770724

CASE SERIES & RETROSPECTIVE STUDIES

• Almatter E, Alsharidah S, Bourhama M, et al. Challenges in managing severe homozygous protein c deficiency: a case report. Blood Coagul Fibrinolysis. 2025;36(1):34-36. doi:10.1097/MBC.0000000000001332
• Appelman EM, Martens ESL, Burger DM, et al. Drug-drug interactions between direct oral anticoagulants and anticancer drugs: A single center daily practice evaluation of the occurrence, prescriber response, and subsequent thrombotic and bleeding complications in the Netherlands. Thromb Res. 2025;245:109232. doi:10.1016/j.thromres.2024.109232
• Budd AN, Parulkar SD, Carabini LM, et al. 4-Factor prothrombin complex concentrates and factor VIII inhibitor bypass activity use in cardiac surgery. Blood Coagul Fibrinolysis. 2025;36(1):18-25. doi:10.1097/MBC.0000000000001335
• Dawwas GK, Cuker A. Comparative effectiveness and safety of rivaroxaban with other oral anticoagulants in older adults with nonvalvular atrial fibrillation: population-based analysis in response to updated Beers Criteria. J Thromb Haemost. 2025;23(2):546-555. doi:10.1016/j.jtha.2024.10.009
• Di Minno MND, Calcaterra IL, Baldacci E, et al. Intensive FVIII replacement in hemophilia patients with hypertrophic synovium: a randomized study. J Thromb Haemost. 2025;23(2):458-465. doi:10.1016/j.jtha.2024.10.018
• Euper M, Schreieck J, Bladt M, et al. Dynamics of Thrombogenicity and Platelet Function and Correlation with Bleeding Risk in Patients Undergoing M-TEER Using the PASCAL System. Thromb Haemost. 2025;125(2):130-141. doi:10.1055/s-0044-1790604
• Gong C, Jiang H, Su Y, et al. Changes in Fibrinogen and D-Dimer During Complicated and Uncomplicated Pregnancy. Int J Lab Hematol. 2025;47(1):156-165. doi:10.1111/ijlh.14382
• Ji Y, Zhang MJ, Wang W, et al. Association of Coagulation Factor XI Level With Cardiovascular Events and Cardiac Function in Community-Dwelling Adults: From ARIC and CHS. Circulation. 2025;151(6):356-367. doi:10.1161/CIRCULATIONAHA.124.070278
• Laguna P, Szczepanska M, Wojdalska M, et al. Real-world safety and efficacy of rADAMTS13 in the treatment of congenital thrombotic thrombocytopenic purpura in pediatric patients in Poland. J Thromb Haemost. 2025;23(2):635-640. doi:10.1016/j.jtha.2024.11.008
• Pezeshkpoor B, Fischer R, Preisler B, et al. Modulation of Haemostatic Balance in Combined von Willebrand Disease and Antithrombin Deficiency: A Comprehensive Family Study. Haemophilia. 2025;31(1):140-147. doi:10.1111/hae.15147
• Saultier P, Grino M, Falaise C, et al. Efficacy and safety of recombinant activated factor VII in Glanzmann thrombasthenia: A systematic literature review. Haemophilia. 2025;31(1):7-15. doi:10.1111/hae.15130

RESEARCH

• Avery NG, Young IR, Lu S, et al. Biophysical characterization of blood coagulation factor VIII binding to lipid nanodiscs that mimic activated platelet surfaces. J Thromb Haemost. 2025;23(2):513-524. doi:10.1016/j.jtha.2024.11.003
• Bär I, Barraclough A, Bürgisser PE, et al. The severe von Willebrand disease variant p.M771V leads to impaired anterograde trafficking of von Willebrand factor in patient-derived and base-edited endothelial colony-forming cells. J Thromb Haemost. 2025;23(2):466-479. doi:10.1016/j.jtha.2024.10.023
• Bender MT, Aggarwal A, Godwin M, et al. Cellular and enzymatic features of thrombi in humans are vascular bed dependent. Blood VTH 2025;2(1):100029. doi:10.1016/j.bvth.2024.100029
• Bouwens BRC, Magdeleyns E, Thomassen MCLGD, et al. Citrullination of tissue factor pathway inhibitor alpha by peptidylarginine deiminase 4 impairs its natural anticoagulant activity toward factors Xa and VIIa/tissue factor and reduces binding to its cofactor protein S. J Thromb Haemost. 2025;23(2):641-650. doi:10.1016/j.jtha.2024.11.009
• Chabata CV, Yu H, Ke L, et al. Andexanet Alfa-Associated Heparin Resistance in Cardiac Surgery: Mechanism and In Vitro Perspectives. Arterioscler Thromb Vasc Biol. 2025;45(1):144-156. doi:10.1161/ATVBAHA.124.321650
• Kruijt M, de la Morena-Barrio ME, Corral J, et al. Novel insights into antithrombin deficiency enabled by mass spectrometry-based precision diagnostics. J Thromb Haemost. 2025;23(1):210-221. doi:10.1016/j.jtha.2024.10.005
• Li Y, Jiang H, Li X, et al. Platelet-Specific Deletion of TGF-β1 Impairs Septic Thrombosis in Mice-Brief Report. Arterioscler Thromb Vasc Biol. 2025;45(1):136-143. doi:10.1161/ATVBAHA.124.322029
• Memon AA, Zöller B, Svensson PJ, et al. Fibrinogen genotypes and their impact on recurrence of venous thromboembolism and family history: A prospective population-based study. Br J Haematol. 2025;206(2):657-665. doi:10.1111/bjh.19999
• Pezeshkpoor B, Sereda N, Becker-Gotot J, et al. Comprehensive evaluation of anti-emicizumab antibodies in acquired hemophilia A: a detailed case study and methodological evaluation. J Thromb Haemost. 2025;23(1):85-96. doi:10.1016/j.jtha.2024.10.003
• Polzin A, Benkhoff M, Thienel M, et al. Long-term FXa inhibition attenuates thromboinflammation after acute myocardial infarction and stroke by platelet proteome alteration. J Thromb Haemost. 2025;23(2):668-683. doi:10.1016/j.jtha.2024.10.025
• Ponzar N, Chinnaraj M, Pagotto A, et al. Mechanistic basis of activation and inhibition of protein disulfide isomerase by allosteric antithrombotic compounds. J Thromb Haemost. 2025;23(2):577-587. doi:10.1016/j.jtha.2024.09.036
• Sim MMS, Mollica MY, Alfar HR, et al. Unfolded Von Willebrand Factor Binds Protein S and Reduces Anticoagulant Activity. Blood VTH. 2025; 2 (1): 100030. doi:10.1016/j.bvth.2024.100030
• Singh S, Hagelueken G, Ugurlar D, et al. Cryo-EM structure of the human native plasma coagulation factor XIII complex. Blood. 2025;145(4):438-449. doi:10.1182/blood.2024025369
• Takahashi Y, Htwe SS, Wang D, et al. Antithrombin regulates neutrophil activities through the stimulation of C-type lectin family 1A. Blood VTH. 2025;2(1):100032. doi:10.1016/j.bvth.2024.100032
• Ward MP, Ibrahim EM, O’Toole SA, et al. Chemotherapy alters thrombomodulin and factor VIIIc expression resulting in acquired activated protein C resistance and enhanced thrombin generation in cancer associated thrombosis. Thromb Res. 2025;246:109251. doi:10.1016/j.thromres.2024.109251
• Wurtzel JGT, Gray BD, Pak KY, et al. Phosphatidylserine-blocking nanoparticles inhibit thrombosis without increased bleeding in mice. J Thromb Haemost. 2025;23(1):108-122. doi:10.1016/j.jtha.2024.10.007
• Xiang B, Wang Y, Rust R, et al. In vivo neuroprotection in ischemic stroke by activated protein C requires β-arrestin 2. Blood VTH 2025;2(1):100037.  doi:10.1016/j.bvth.2024.100037
• York ES, Dratch BD, Ito J, et al. Persistent splenic-derived IgMs preferentially recognize factor VIII A2 and C2 domain epitopes but do not alter antibody production. J Thromb Haemost. 2025;23(2):440-457. doi:10.1016/j.jtha.2024.10.017

METHODS

• Carré J, Demont Y, Mouton C, et al. Imaging flow cytometry as a novel approach for the diagnosis of heparin-induced thrombocytopenia. Br J Haematol. 2025;206(2):666-674. doi:10.1111/bjh.19945
• Drissi E, Ben Lakhal F, Ghali O, et al. Clot waveform analysis in hemophilia carriers. Blood Coagul Fibrinolysis. 2025;36(1):8-13. doi:10.1097/MBC.0000000000001331
• Kitchen M, Bryant M, Brown P, et al. Frozen/Thawed Samples Can Replace Fresh Samples for Assignment of ISI to Secondary Thromboplastin Standards for Multiple Reagent/Instrument Combinations: Data to Support Possible Revision of WHO Guidelines. Int J Lab Hematol. 2025;47(1):140-148. doi:10.1111/ijlh.14369
• Kuktić I, Pašalić A, Čančarević O, et al. The determination of euglobulin clot lysis time reference intervals in Beckton Dickinson and Kima 3.2% sodium citrate coagulation tubes. Blood Coagul Fibrinolysis. 2025;36(1):14-17. doi:10.1097/MBC.0000000000001334
• Nilius H, Naas S, Studt JD, et al. The dynamic range of immunoassays for heparin-induced thrombocytopenia. J Thromb Haemost. 2025;23(2):684-691. doi:10.1016/j.jtha.2024.10.026
• Srivaths L, Larson J, Saroukhani S, et al. Comparing one stage, chromogenic assay results and discrepancies with bleeding phenotype and genetic variants in females with hemophilia A. J Thromb Haemost. 2025;23(2):504-512. doi:10.1016/j.jtha.2024.10.030
• Trossaërt M, Genre-Volot F, Horvais V, et al. Does the VWF:CB Assay Help to Diagnose von Willebrand Factor Deficiency in Patients With a Bleeding Disorder of Unknown Cause?. Int J Lab Hematol. 2025;47(1):149-155. doi:10.1111/ijlh.14371
• Zhao Z, Wang Y, Yang A, et al. A novel role for thioredoxin-related transmembrane protein TMX4 in platelet activation and thrombus formation. J Thromb Haemost. 2025;23(1):277-292. doi:10.1016/j.jtha.2024.09.007